See more : Olivut Resources Ltd. (OLVRF) Income Statement Analysis – Financial Results
Complete financial analysis of Allergy Therapeutics plc (AGYTF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Allergy Therapeutics plc, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Nancal Technology Co.,Ltd (603859.SS) Income Statement Analysis – Financial Results
- K&O Energy Group Inc. (1663.T) Income Statement Analysis – Financial Results
- DFM Foods Limited (DFMFOODS.NS) Income Statement Analysis – Financial Results
- Investec Group (INVP.L) Income Statement Analysis – Financial Results
- Xiandai Investment Co.,Ltd (000900.SZ) Income Statement Analysis – Financial Results
Allergy Therapeutics plc (AGYTF)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.allergytherapeutics.com
About Allergy Therapeutics plc
Allergy Therapeutics plc, a biotechnology company, engages in the research and development of allergy treatments. The company sells injectable and sublingual allergen-specific immunotherapies; and offers prescription for the treatment of pollen-related allergies particularly to grasses, weeds, and trees, as well as diagnostics. Its products include Pollinex Quattro, Oralvac, Venomil, ImmunoBON, Synbiotics, Acarovac Plus, Penicillin diagnostics, Pollinex, and VLP Peanut. The company also develops allergy vaccines for trees, grass, house dust mite, and pets with fur/hair, as well as peanut allergy vaccines. It operates in Central Europe, Southern Europe, the United Kingdom, and internationally. Allergy Therapeutics plc was incorporated in 2004 and is headquartered in Worthing, the United Kingdom.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 55.20M | 59.59M | 72.77M | 84.33M | 78.20M | 73.72M | 68.35M | 64.14M | 48.51M | 43.23M | 41.96M | 39.28M | 41.28M | 41.55M | 40.75M | 37.76M | 31.02M | 25.74M | 23.56M | 20.61M | 18.00M | 17.33M | 15.14M |
| Cost of Revenue | 25.46M | 26.34M | 23.26M | 22.11M | 20.20M | 18.38M | 17.01M | 16.77M | 14.07M | 12.18M | 11.95M | 11.95M | 13.67M | 13.22M | 11.16M | 13.56M | 10.87M | 10.07M | 6.51M | 4.85M | 5.51M | 5.33M | 5.27M |
| Gross Profit | 29.74M | 33.25M | 49.51M | 62.23M | 58.00M | 55.34M | 51.33M | 47.37M | 34.44M | 31.05M | 30.00M | 27.33M | 27.61M | 28.33M | 29.59M | 24.19M | 20.16M | 15.67M | 17.05M | 15.75M | 12.49M | 12.00M | 9.87M |
| Gross Profit Ratio | 53.87% | 55.79% | 68.03% | 73.79% | 74.17% | 75.07% | 75.11% | 73.85% | 71.00% | 71.83% | 71.51% | 69.57% | 66.88% | 68.18% | 72.60% | 64.08% | 64.98% | 60.89% | 72.35% | 76.45% | 69.37% | 69.26% | 65.18% |
| Research & Development | 22.90M | 20.12M | 15.66M | 12.89M | 5.85M | 6.95M | 16.02M | 9.30M | 16.22M | 3.12M | 2.96M | 2.54M | 2.10M | 1.67M | 2.21M | 5.30M | 16.30M | 25.34M | 9.56M | 5.62M | 451.00K | 527.00K | 2.54M |
| General & Administrative | 22.79M | 25.18M | 20.83M | 20.67M | 19.63M | 17.60M | 15.54M | 13.78M | 10.09M | 10.22M | 7.99M | 7.85M | 15.18M | -8.29M | -6.03M | -14.74M | -12.71M | -11.14M | -6.81M | -4.96M | -2.23M | 0.00 | 0.00 |
| Selling & Marketing | 19.59M | 23.71M | 26.00M | 25.20M | 24.85M | 27.00M | 27.13M | 26.89M | 20.22M | 17.06M | 17.92M | 16.28M | 17.88M | 17.52M | 16.14M | 14.89M | 12.85M | 11.31M | 9.83M | 8.01M | 6.57M | 0.00 | 0.00 |
| SG&A | 42.38M | 48.88M | 46.83M | 45.87M | 44.48M | 44.59M | 42.68M | 40.67M | 30.32M | 27.28M | 25.91M | 24.12M | 33.06M | 9.23M | 10.12M | 158.00K | 147.00K | 169.00K | 3.03M | 3.05M | 4.34M | 0.00 | 0.00 |
| Other Expenses | -287.00K | 3.89M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -154.00K | -171.00K | -191.00K | 0.00 | 0.00 | 0.00 | -196.00K | -193.00K | 3.37M | 367.00K | 31.00K | -350.00K | -262.00K | -34.00K | 0.00 | 0.00 |
| Operating Expenses | 64.99M | 72.90M | 61.75M | 58.19M | 49.69M | 50.95M | 58.06M | 49.26M | 46.39M | 30.33M | 28.80M | 26.66M | 35.16M | 28.39M | 28.01M | 32.68M | 44.71M | 50.92M | 24.80M | 18.95M | 10.93M | 13.57M | 14.07M |
| Cost & Expenses | 90.46M | 99.24M | 85.01M | 80.30M | 69.90M | 69.33M | 75.08M | 66.03M | 60.46M | 42.51M | 40.75M | 38.61M | 48.83M | 41.62M | 39.17M | 46.25M | 55.58M | 60.99M | 31.31M | 23.81M | 16.45M | 18.90M | 19.34M |
| Interest Income | 285.00K | 329.00K | 257.00K | 117.00K | 266.00K | 103.00K | 154.00K | 151.00K | 180.00K | 147.00K | 170.00K | 19.00K | 5.00K | 2.00K | 9.00K | 30.00K | 201.00K | 647.00K | 545.00K | 531.00K | 60.00K | 33.00K | 24.00K |
| Interest Expense | 4.11M | 2.44M | 669.00K | 491.00K | 504.00K | 201.00K | 320.00K | 225.00K | 293.00K | 218.00K | 308.00K | 404.00K | 457.00K | 1.54M | 1.79M | 3.24M | 1.97M | 131.00K | 4.00K | 42.00K | 26.00K | 39.00K | 545.00K |
| Depreciation & Amortization | 4.32M | 4.22M | 4.17M | 4.13M | 3.91M | 2.09M | 2.02M | 1.94M | 1.67M | 1.29M | 1.29M | 1.34M | 1.89M | 1.70M | 1.43M | 1.32M | 1.16M | 955.00K | 1.12M | 884.00K | 319.00K | 944.00K | 1.92M |
| EBITDA | -30.74M | -35.10M | -7.82M | 8.28M | 12.49M | 6.58M | -4.56M | 191.00K | -10.56M | 2.17M | 2.68M | 2.03M | 2.99M | 727.00K | 3.10M | -6.89M | -17.11M | -24.67M | -5.38M | -1.00M | 1.94M | 5.24M | -2.31M |
| EBITDA Ratio | -55.69% | -58.91% | -10.75% | 9.82% | 15.97% | 8.93% | -6.67% | 0.30% | -20.83% | 5.01% | 6.35% | 5.17% | 7.24% | 0.70% | 7.19% | -15.11% | -55.17% | -95.76% | -21.40% | -6.11% | 10.75% | 13.49% | -14.93% |
| Operating Income | -35.26M | -39.65M | -12.25M | 4.03M | 8.31M | 4.39M | -6.73M | -1.90M | -11.95M | 725.00K | 1.21M | 668.00K | 1.09M | 115.00K | 1.46M | 5.10M | 15.59M | 26.28M | 6.71M | 2.42M | 1.56M | 1.39M | 4.25M |
| Operating Income Ratio | -63.87% | -66.55% | -16.83% | 4.78% | 10.62% | 5.96% | -9.85% | -2.96% | -24.64% | 1.68% | 2.88% | 1.70% | 2.65% | 0.28% | 3.57% | 13.52% | 50.26% | 102.07% | 28.50% | 11.73% | 8.64% | 8.04% | 28.08% |
| Total Other Income/Expenses | -3.91M | -2.11M | -412.00K | -374.00K | -238.00K | -98.00K | -166.00K | -74.00K | -113.00K | -71.00K | -125.00K | -139.00K | -452.00K | -2.43M | -1.57M | -16.54M | -35.84M | -52.03M | -12.89M | -4.61M | 34.00K | 2.87M | -9.02M |
| Income Before Tax | -39.17M | -41.77M | -12.66M | 3.66M | 8.07M | 4.29M | -6.90M | -1.97M | -12.06M | 654.00K | 1.08M | 432.00K | 640.00K | -2.31M | -116.00K | -11.44M | -20.24M | -25.76M | -6.17M | -2.19M | 1.59M | 4.26M | -4.77M |
| Income Before Tax Ratio | -70.95% | -70.09% | -17.39% | 4.34% | 10.32% | 5.82% | -10.09% | -3.07% | -24.87% | 1.51% | 2.58% | 1.10% | 1.55% | -5.57% | -0.28% | -30.29% | -65.26% | -100.07% | -26.20% | -10.63% | 8.83% | 24.58% | -31.52% |
| Income Tax Expense | 1.05M | 1.31M | 1.12M | 771.00K | 1.01M | 826.00K | 637.00K | 511.00K | 1.01M | 546.00K | 343.00K | -104.00K | -183.00K | 349.00K | -702.00K | 326.00K | 53.00K | -2.50M | -12.87M | -4.56M | 372.00K | -916.00K | -109.00K |
| Net Income | -40.22M | -43.07M | -13.78M | 2.89M | 7.06M | 3.47M | -7.53M | -2.48M | -13.07M | 108.00K | 741.00K | 633.00K | 823.00K | -2.66M | 586.00K | -11.76M | -20.30M | -23.26M | -6.17M | -2.19M | 1.22M | 5.18M | -4.66M |
| Net Income Ratio | -72.86% | -72.28% | -18.93% | 3.42% | 9.03% | 4.70% | -11.02% | -3.87% | -26.95% | 0.25% | 1.77% | 1.61% | 1.99% | -6.41% | 1.44% | -31.16% | -65.43% | -90.34% | -26.20% | -10.63% | 6.77% | 29.87% | -30.80% |
| EPS | 0.00 | -0.06 | -0.01 | 0.00 | 0.01 | 0.00 | -0.01 | 0.00 | -0.02 | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 | 0.00 | -0.14 | -0.25 | -0.28 | -0.09 | -0.04 | 0.03 | 0.08 | -0.07 |
| EPS Diluted | 0.00 | -0.06 | -0.01 | 0.00 | 0.00 | 0.00 | -0.01 | 0.00 | -0.02 | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 | 0.00 | -0.14 | -0.25 | -0.28 | -0.09 | -0.04 | 0.03 | 0.08 | -0.07 |
| Weighted Avg Shares Out | 0.00 | 669.84M | 1.40B | 1.39B | 1.38B | 1.37B | 595.10M | 592.19M | 570.34M | 475.20M | 451.54M | 408.39M | 326.80M | 310.76M | 293.14M | 81.99M | 81.95M | 81.95M | 66.12M | 57.47M | 40.94M | 62.95M | 62.95M |
| Weighted Avg Shares Out (Dil) | 0.00 | 670.36M | 1.40B | 1.47B | 1.46B | 1.45B | 595.10M | 592.19M | 570.34M | 498.24M | 471.51M | 427.02M | 340.05M | 323.35M | 305.58M | 81.99M | 81.95M | 81.95M | 66.12M | 57.47M | 49.29M | 62.95M | 62.95M |
Allergy Therapeutics provides further guidance after a strong year
Allergy Therapeutics PLC (LON:AGY) has fleshed out June's trading statement in which it said operating profit would be well ahead of expectations. In the latest update, it told investors revenues would also beat forecasts.
Allergy Therapeutics showcases latest advances
Allergy Therapeutics PLC (LON:AGY) is making presentations in the coming days on some of the advances made by its researchers. The new information will be shared via posters at the European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress taking...
Allergy Therapeutics ends financial year on a high with operating profits 'well ahead' of expectations
Allergy Therapeutics PLC (LON:AGY) said operating profit was strong and expected to be “well ahead" of expectations as it updated the market on current trading. It said robust sales growth was helped by the Euro exchange rate, which was “reflective of...
Allergy Therapeutics ends the financial year on a high with operating profits 'well ahead' of expectations
Allergy Therapeutics PLC (LON:AGY) said operating profit was strong and expected to be “well ahead" of expectations as it updated the market on current trading. It said that robust sales growth was helped by the Euro exchange rate, which was “reflective...
Allergy Therapeutics hails conclusion of 'breakthrough' hay fever field study
Allergy Therapeutics PLC (LON:AGY) said it has completed the treatment of all patients taking part in an exploratory field study of its short-course inoculation against grass pollen-induced hay fever. Assessing the safety and efficacy of the new injection, results from...
Allergy Therapeutics makes strong start to financial year unimpeded by lockdown and Brexit
Allergy Therapeutics PLC (LON:AGY) posted record profits for the six-month stage as the group, which, as the name suggests, specialises in allergy treatments for conditions such as hay fever, emerged from the period in rude health. On revenues up 7%...
Source: https://incomestatements.info
Category: Stock Reports